Based upon previous reports supporting niclosamide’s ability to decrease AR/AR-SV protein levels, as well as decrease the activity of multiple oncogenic pathways, we decided to evaluate niclosamide and two previously reported analogs with anti-AR effects, compound #7 and compound #11, for use in HCC (Figure 3A) [32]. The gene discussed is AR; the disease is hepatocellular carcinoma.